This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnershipShort Interest About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) Get CRNX alerts:Sign Up Key Stats Today's Range$84.95▼$84.9550-Day Range$83.52▼$84.9552-Week Range$30.25▼$85.01VolumeN/AAverage Volume2.43 million shsMarket Capitalization$9.01 billionP/E RatioN/ADividend YieldN/APrice Target$83.44Consensus RatingHold Company Overview Crinetics Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing orally delivered, small-molecule therapies for endocrine conditions and other hormone-related diseases. The company’s research is centered on medicines designed to act on peptide hormone receptors, with the goal of providing alternatives to injectable therapies. Crinetics’ lead product candidate is paltusotine, an oral, selective somatostatin receptor type 2 agonist being developed for the treatment of acromegaly, a rare disorder caused by excessive growth hormone production. The company is also developing atumelnant, formerly known as CRN04894, an oral adrenocorticotropic hormone receptor antagonist being investigated for conditions including congenital adrenal hyperplasia and Cushing’s disease. Founded in 2008 and headquartered in San Diego, California, Crinetics conducts research and clinical development activities intended to serve patients in the United States and international markets. The company’s leadership includes founder and Chief Executive Officer Scott Struthers, Ph.D., who has guided the organization’s focus on orally administered therapies for endocrine disorders.AI Generated. May Contain Errors. Read More Crinetics Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreCRNX MarketRank™: 0.21139705882 of 5 starsCrinetics Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat, and ranked 848th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingHold Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on no strong buy ratings, 3 buy ratings, 11 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Crinetics Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to grow in the coming year, from ($4.83) to ($4.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -16.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 7.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for CRNX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRNX Stock News HeadlinesCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P TMI IndexSeptember 3, 2026 | marketscreener.comMCrinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Global BMI IndexSeptember 3, 2026 | marketscreener.comMTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system. | Banyan Hill Publishing (Ad)Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from S&P Pharmaceuticals Select Industry IndexSeptember 3, 2026 | marketscreener.comMVertex Pharmaceuticals Closes Crinetics Pharmaceuticals AcquisitionSeptember 1, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—CRNX, PSBQ, D, and NEEAugust 7, 2026 | globenewswire.comCrinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 3, 2026 | globenewswire.comAre CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?July 21, 2026 | prnewswire.comSee More Headlines CRNX Stock Analysis - Frequently Asked Questions How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings results on Monday, August, 3rd. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.18) by $0.04. The company's revenue was up 2336.9% on a year-over-year basis. When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $96 million in an IPO on Wednesday, July 18th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Plug Power (PLUG), Micron Technology (MU), NIO (NIO), Tesla (TSLA), Advanced Micro Devices (AMD) and Alphabet (GOOG). Company Calendar Last Earnings8/03/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CRNX's financial health is in the Green zone, according to TradeSmith. CRNX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CRNX CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year Founded2008Price Target and Rating Average Price Target for Crinetics Pharmaceuticals$83.44 High Price Target$95.00 Low Price Target$67.00 Potential Upside/Downside-1.8%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($5.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$465.32 million Net Margins-1,189.88% Pretax Margin-1,189.45% Return on Equity-44.22% Return on Assets-39.77% Debt Debt-to-Equity RatioN/A Current Ratio15.57 Quick Ratio15.53 Sales & Book Value Annual Sales$7.70 million Price / Sales1,170.54 Cash FlowN/A Price / Cash FlowN/A Book Value$11.23 per share Price / Book7.56Miscellaneous Outstanding Shares106,100,000Free Float102,063,000Market Cap$9.01 billion OptionableOptionable Beta0.08 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRNX) was last updated on 9/1/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredStop picking AI winners. Start collecting every ThursdayOne fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution ...Investors Alley | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"Do not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
